Financial Performance - BridgeBio Pharma reported a quarterly loss of $0.95 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.83, representing an earnings surprise of -14.46% [1] - The company posted revenues of $110.57 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 14.95%, compared to revenues of $2.17 million a year ago [2] - Over the last four quarters, BridgeBio Pharma has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - BridgeBio Pharma shares have increased approximately 74% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.61 on revenues of $136.32 million, and for the current fiscal year, it is -$3.16 on revenues of $466.56 million [7] - The estimate revisions trend for BridgeBio Pharma was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Generic Drugs industry, to which BridgeBio Pharma belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]